1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Actelion's Opsumit Shows MERIT In CTEPH

 
• By John Davis

The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.

Swiss biotech Actelion Pharmaceuticals Ltd. is not only trying to diversify its product portfolio away from pulmonary arterial hypertension (PAH), with Phase III drugs in multiple sclerosis (ponesimod) and Clostridium difficile infection (cadazolid), it is also “committed to remaining a leader in the pulmonary hypertension field,” according to CEO Jean-Paul Clozel.

Extending the reach of marketed drugs with broader indications and line extensions is a well-trodden path for pharmaceutical companies, and Actelion is no exception

More from Respiratory

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.